Uncategorized

03/21/2024

JFK Airport Chooses LOGIPIX for Airside Virtual Ramp Control System

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground. LOGIPIX, a global leader in

01/15/2024

Polykon Manufacturing LLC merges with Seppic Inc. and becomes Seppic Inc. Richmond

Since its opening in 2020 in Richmond, Virginia, the Polykon Manufacturing LLC facility has strengthened Seppic’s proximity to our North American customers and expanded our manufacturing capabilities. Effective January 1, 2024, Polykon Manufacturing LLC took the next step by merging with its parent company, Seppic Inc. This change brings consistency to the organization of Seppic’s

09/12/2023

Virginia Coordinated Clinical Research Network Launched to Focus on Clinical Trial Research, Developing Medical Treatments, Scientific Advancements, and Real-World Applications

From the development of new medicines and cancer treatments to gene therapy and advances in scientific understanding of serious conditions such as Alzheimer’s disease, clinical research is helping drive the future of medical innovation and patient care. To further support that work, a coalition of health care systems, institutions of higher education, and other organizations

06/21/2023

Children’s National Hospital Receives $96 Million Investment for Rare Pediatric Brain Tumor Research & Care

Children’s National Hospital announced a $96 million investment from an anonymous donor family that strengthens its globally recognized leadership to transform rare childhood brain tumor research and care. It is one of the largest donations in the hospital’s history. It allows Children’s National to recruit more top talent and advance the most promising research for

06/09/2023

Apply Now: 📣 BLUE KNIGHT ™️ Resident QuickFire Challenge: Accelerating Project NextGen

Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), is proud to launch the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen. Current and alumni Blue Knight residents and their collaborators are invited to submit promising potential pre-clinical or clinical solutions for the opportunity to receive award funding from a

05/31/2023

Apply Now: BLUE KNIGHT™ QuickPitch: Activating for the Future

Recent global disease outbreaks have had devastating impacts, triggering a renewed emphasis on preparation for potential known and unknown health threats. By proactively enhancing preparedness against emerging pathogens, we aim to minimize the scale of future outbreaks, protect vulnerable populations, and ultimately safeguard our health security. To that end, Johnson & Johnson Innovation, together with

01/20/2023

$100M donor gift to launch U.Va. biotech institute

Charlottesville, VA, /Virginia Business/ – The University of Virginia will build a biotechnology institute funded with a $100 million donation from Charlottesville investor Paul Manning and his wife, Diane, the university announced Friday. Along with the Mannings’ gift, U.Va. will contribute $150 million, and the state has allocated $50 million in initial investments for the institute

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

05/03/2022

AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases

CHARLOTTESVILLE, Va., – AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma. Revealed in the peer-reviewed journal Science Advances, the paper details AMPEL’s breakthrough machine learning approach to characterize disease activity from gene expression data obtained

04/25/2022

Caretaker Medical Receives FDA Clearance for 4 new Non-Invasive Hemodynamic Parameters

Caretaker Medical, a digital health leader in continuous “beat by beat” wireless patient monitoring technologies, announced that it has received FDA 510(k) Clearance for four new continuous hemodynamic parameters, adding cardiac output, stroke volume, heart rate variability, and left ventricular ejection time to its VitalStream™ non-invasive patient monitoring platform. This is the company’s 5th FDA

04/06/2022

FDA Clears ReAlta Life Sciences’ Phase 2 STAR Trial of RLS-0071 in Neonates with Hypoxic-Ischemic Encephalopathy

RLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and other rare diseases Norfolk, VA, ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, today announced U.S. Food and

03/21/2022

It’s Time for NIH to Uphold the Law, Once Again

“As then NIH Director Elias Zerhouni noted in 2004 while rejecting the first march in petition seeking to impose price controls on a successfully commercialized product: ‘… the extraordinary remedy of march-in rights is not an appropriate means of controlling prices.’ That was correct then and remains so today.” /IPWatchdog /As discussed previously, the critics are in full howl

02/24/2022

Do you want to help support student interns? Apply Now!

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over

11/23/2021

ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Develop Research Capabilities in Infectious, Immunologic, and Allergic Diseases

ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $545 million by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). With this contract, ATCC will support NIAID’s

10/20/2021

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee

10/14/2021

Bonumose Inc. to invest $27.7M in Albemarle County expansion

Virginia sugar alternatives company Bonumose Inc. will invest $27.7 million to expand in Albemarle County in a partnership with The Hershey Co. to research and develop reduced or zero sugar chocolate products, creating 64 jobs, Gov. Ralph Northam announced. Bonumose will move into 36,000 square feet of the former State Farm building to increase production

10/12/2021

Fralin Biomedical Research Institute officially opens $90 million addition

State and local officials gathered for the grand opening of the newest building at the Fralin Biomedical Research Institute in Roanoke. The COVID-19 pandemic delayed the ribbon-cutting ceremony for the 139,000-square-foot addition, which opened to researchers and staff last summer. The building, located at 4 Riverside Circle on the Virginia Tech Carilion Health Sciences campus,

09/30/2021

FDA Clears Caretaker Medical’s Wireless Platform for Continuous Noninvasive Blood Pressure and Hemodynamic Monitoring

Caretaker Medical, a pioneer in wireless “beat by beat” continuous, non-invasive, advanced patient monitoring, announced U.S. Food and Drug Administration (FDA) clearance of the company’s next-generation VitalStream™ wireless blood pressure and hemodynamic monitoring platform. Continuous monitoring of blood pressure is of great importance to detect and treat dynamic changes. Traditionally, blood pressure is measured intermittently

09/20/2021

BASF Adopts BrightSpec’s Broadband MRR Technology for Structural Elucidation

BrightSpec announced the start of operation of a broadband Molecular Rotational Resonance spectrometer at BASF’s research center in Ludwigshafen, Germany. BASF will utilize MRR spectroscopy for the concise structure elucidation of organic compounds where isomerism is an underlying question. Major applications comprise stereochemical analysis, including chirality, defining the composition of mixtures without purification, and the

08/12/2021

FDA Solicits Feedback on Drug Products Approved Under Abbreviated New Drug Applications Before the Enactment of the Hatch-Waxman Amendments

The FDA has established a public docket to solicit comments on several issues related to FDA’s regulation of certain drug products approved under abbreviated new drug applications before the enactment of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. Because these Pre-Hatch-Waxman ANDAs (PANDAs) were submitted under